Profound Medical Corp. (TSX:PRN)
Canada · Delayed Price · Currency is CAD 9.65
-0.07 (-0.72%)
Aug 13, 2026, 11:11 AM EST
Profound Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8.63 | 6.37 | 2.44 | 0.39 | 2 | 3.15 |
Other Revenue | 10.45 | 9.73 | 8.24 | 6.81 | 4.68 | 3.72 |
| 19.09 | 16.1 | 10.68 | 7.2 | 6.68 | 6.87 | |
Revenue Growth | 61.20% | 50.73% | 48.35% | 7.75% | -2.79% | -5.90% |
Cost of Revenue | 5.39 | 4.71 | 3.64 | 2.89 | 3.66 | 3.92 |
Gross Profit | 13.7 | 11.39 | 7.04 | 4.31 | 3.02 | 2.95 |
Selling, General & Admin | 28.46 | 32.05 | 23.13 | 18.54 | 17.93 | 17.97 |
Research & Development | 20.61 | 20.6 | 16.97 | 14.42 | 14.69 | 15.28 |
Operating Expenses | 49.07 | 52.65 | 40.1 | 32.96 | 32.62 | 33.24 |
Operating Income | -35.37 | -41.25 | -33.06 | -28.65 | -29.6 | -30.29 |
Interest Expense | - | - | - | - | -0.17 | -0.07 |
Interest & Investment Income | 1 | 1.07 | 1.44 | 0.78 | 0.8 | 0.21 |
Currency Exchange Gain (Loss) | 1.86 | -2.13 | 3.81 | -0.58 | 3.1 | -0.29 |
Other Non Operating Income (Expenses) | - | - | - | - | 0.02 | -0.16 |
EBT Excluding Unusual Items | -32.52 | -42.32 | -27.82 | -28.45 | -25.86 | -30.59 |
Impairment of Goodwill | - | - | - | - | -2.52 | - |
Pretax Income | -32.52 | -42.32 | -27.82 | -28.45 | -28.38 | -30.59 |
Income Tax Expense | 0.23 | 0.25 | -0 | -0.13 | 0.29 | 0.11 |
Net Income | -32.74 | -42.57 | -27.82 | -28.32 | -28.67 | -30.7 |
Net Income to Common | -32.74 | -42.57 | -27.82 | -28.32 | -28.67 | -30.7 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 33 | 30 | 25 | 21 | 21 | 20 |
Shares Outstanding (Diluted) | 33 | 30 | 25 | 21 | 21 | 20 |
Shares Change | 20.87% | 22.08% | 16.91% | 1.69% | 1.79% | 18.33% |
EPS (Basic) | -0.98 | -1.41 | -1.12 | -1.34 | -1.38 | -1.50 |
EPS (Diluted) | -0.98 | -1.41 | -1.12 | -1.34 | -1.38 | -1.50 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -36.28 | -38.38 | -23.45 | -22.61 | -25.8 | -22.39 |
Free Cash Flow Per Share | -1.09 | -1.27 | -0.95 | -1.07 | -1.24 | -1.09 |
Gross Margin | 71.79% | 70.77% | 65.89% | 59.90% | 45.22% | 42.95% |
Operating Margin | -185.31% | -256.27% | -309.57% | -397.99% | -443.08% | -440.73% |
Profit Margin | -171.56% | -264.44% | -260.45% | -393.43% | -429.11% | -446.66% |
Free Cash Flow Margin | -190.07% | -238.43% | -219.60% | -314.06% | -386.17% | -325.80% |
EBITDA | -34.88 | -40.69 | -32.13 | -27.72 | -28.83 | -29.61 |
EBITDA Margin | -182.74% | -252.79% | - | - | - | - |
D&A For EBITDA | 0.49 | 0.56 | 0.94 | 0.93 | 0.78 | 0.68 |
EBIT | -35.37 | -41.25 | -33.06 | -28.65 | -29.6 | -30.29 |
EBIT Margin | -185.31% | -256.27% | - | - | - | - |
Revenue as Reported | 19.09 | 16.1 | 10.68 | 7.2 | 6.68 | 6.87 |